Table 1.
Patient baseline demographics
| Amlodipine/atorvastatin | Amlodipine + atorvastatin | Amlodipine + other statin | Other CCB + atorvastatin | Other CCB + other statin | |
| Patients | |||||
| (N = 4703) | n = 795 | n = 735 | n = 1163 | n = 652 | n = 1358 |
| Ageb, mean (SD) years | 61.4 (12.0) | 62.8 (12.6) | 63.1 (12.1) | 62.1 (11.4) | 64.4 (12.3) |
| Femaleb, % | 42.5 | 55.6 | 47.8 | 57.5 | 55.3 |
| Drugs at baselineb, mean (SD) | 6.0 (5.0) | 8.1 (5.0) | 8.2 (5.1) | 8.2 (5.1) | 8.1 (5.3) |
| Business typeb, % | |||||
| Commercial (MCO) | 81.0 | 68.8 | 75.5 | 66.4 | 56.4 |
| Medicaid | 2.4 | 17.1 | 7.9 | 19.2 | 9.7 |
| Medicare | 0.9 | 1.9 | 3.3 | 2.0 | 18.3 |
| Self-insured | 15.7 | 10.5 | 12.0 | 10.0 | 10.7 |
| Number of drug classes utilized(b,c) | 6.6 | 7.4 | 7.6 | 7.6 | 7.5 |
| Maintenance medication refilla, % | 57.1 | 60.9 | 62.5 | 60.3 | 59.9 |
| Statin (CCB new start)b, % | 61.3 | 54.5 | 62.9 | 36.5 | 42.3 |
| CCB (statin new start)b, % | 38.6 | 45.4 | 37.0 | 63.4 | 57.6 |
| Medication usage, % | |||||
| ACE inhibitorb | 36.6 | 46.5 | 43.4 | 41.2 | 42.4 |
| Beta-blockerb | 36.8 | 42.8 | 43.5 | 31.7 | 29.3 |
| Diuretica | 9.4 | 14.9 | 15.2 | 14.4 | 13.8 |
| ARBb | 29.3 | 19.4 | 24.0 | 17.3 | 13.5 |
| Coronary vasodilatora | 8.4 | 12.5 | 12.2 | 11.0 | 9.7 |
| Digoxinb | 1.5 | 2.9 | 4.1 | 5.6 | 5.8 |
| Platelet aggregation inhibitorb | 11.1 | 10.2 | 10.0 | 9.0 | 5.8 |
| Antidiabetic agenta | 25.5 | 30.2 | 32.4 | 31.4 | 28.6 |
| Antidepressanta | 17.2 | 20.5 | 19.3 | 22.3 | 22.3 |
a
p < 0.05;
b
p < 0.0001 tests for differences among all cohorts
c
Number of drugs classes utilized based on First DataBank (First DataBank Inc. 2006) therapeutic categories.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; MCO, managed care organization.